Trispecific antibodies that engage NK cells by simultaneous binding to NKp46 and CD16 on NK cells and to a specific antigen on cancer cells show higher potency than current clinically available therapeutic antibodies generated against the same cancer antigen [21]. This evidence concerns the gene FCGR3B and cancer.